Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that gets the New York drugmaker ...

Pfizer enters the obesity drug market with its Metsera acquisition, aiming to challenge leaders Eli Lilly and Novo Nordisk.

Pfizer said on Monday it would acquire weight-loss drug developer Metsera in a deal valued at up to $7.3 billion, including ...

The acquisition will mark Pfizer’s reentry into the weight-loss market after the failure of its GLP-1 drug candidate ...

The FDA has approved Keytruda Qlex, a faster, under-the-skin cancer treatment offering convenience and flexibility. Here's ...

The FDA has approved a new injectable version of cancer drug Keytruda as Merck seeks to protect its market dominance.  Here are five things to know: ...

Pfizer will acquire Metsera for nearly $5B, boosting its push into obesity treatments with potential oral and injectable drugs.

Lexicon Pharmaceuticals said on Monday it had submitted supplementary data to the U.S. Food and Drug Administration to enhance the benefit-risk profile of its experimental drug, zynquista, for ...